These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25096867)

  • 41. Bisphosphonates and orthodontics.
    Goss AN
    Aust Orthod J; 2008 May; 24(1):56-7. PubMed ID: 18649566
    [No Abstract]   [Full Text] [Related]  

  • 42. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta.
    Weber M; Roschger P; Fratzl-Zelman N; Schöberl T; Rauch F; Glorieux FH; Fratzl P; Klaushofer K
    Bone; 2006 Sep; 39(3):616-22. PubMed ID: 16644299
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cyclic bisphosphonate therapy reduces pain and improves physical functioning in children with osteogenesis imperfecta.
    Garganta MD; Jaser SS; Lazow MA; Schoenecker JG; Cobry E; Hays SR; Simmons JH
    BMC Musculoskelet Disord; 2018 Sep; 19(1):344. PubMed ID: 30249227
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T; Turan S; Guran T; Bereket A
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Surgery versus surgery plus pamidronate in the management of osteogenesis imperfecta patients: a comparative study.
    el-Sobky MA; Hanna AA; Basha NE; Tarraf YN; Said MH
    J Pediatr Orthop B; 2006 May; 15(3):222-8. PubMed ID: 16601594
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cyclic intravenous pamidronate in a very low-birthweight infant with osteogenesis imperfecta.
    Eto S; Hada S; Fukuhara R; Nishimura G; Takagi M
    Pediatr Int; 2018 May; 60(5):485-486. PubMed ID: 29700899
    [No Abstract]   [Full Text] [Related]  

  • 47. Decrease of serum alkaline phosphatase after three cycles of pamidronate disodium in children with severe osteogenesis imperfecta.
    Cabral de Menezes Filho H; Rodrigues JM; Radonsky V; Della Manna T; Kuperman H; Steinmetz L; Dichtchekenian V; Damiani D; Setian N
    Horm Res; 2007; 68 Suppl 5():207-8. PubMed ID: 18174750
    [No Abstract]   [Full Text] [Related]  

  • 48. Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long?
    Rauch F; Glorieux FH
    Ann Med; 2005; 37(4):295-302. PubMed ID: 16019729
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Osteogenesis imperfecta.
    Bhadada SK; Santosh R; Bhansali A; Upreti V; Dutta P
    J Assoc Physicians India; 2009 Jan; 57():33-6. PubMed ID: 19753756
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The clinical and radiological assessment of cyclic intravenous pamidronate administration in children with osteogenesis imperfecta.
    Adiyaman P; Ocal G; Berberoğlu M; Evliyaoğlu O; Aycan Z; Cetinkaya E
    Turk J Pediatr; 2004; 46(4):322-8. PubMed ID: 15641265
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metaphyseal sclerosis associated with bisphosphonate therapy.
    Damiani D
    J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1167. PubMed ID: 18183786
    [No Abstract]   [Full Text] [Related]  

  • 52. Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy.
    D'Eufemia P; Finocchiaro R; Zambrano A; Tetti M; Ferrucci V; Celli M
    Biomed Pharmacother; 2007 May; 61(4):235-40. PubMed ID: 17275249
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta.
    González E; Pavía C; Ros J; Villaronga M; Valls C; Escolá J
    J Pediatr Endocrinol Metab; 2001 May; 14(5):529-33. PubMed ID: 11393574
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alendronate treatment in osteogenesis imperfecta.
    Madenci E; Yilmaz K; Yilmaz M; Coskun Y
    J Clin Rheumatol; 2006 Apr; 12(2):53-6. PubMed ID: 16601536
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pulmonary function tests in an infant with osteogenesis imperfecta and early biphosphonate treatment.
    Rugolotto S; Monti E; Carli M; Pietrobelli A; Antoniazzi F; Tato L
    Acta Paediatr; 2007 Dec; 96(12):1856-7. PubMed ID: 18001342
    [No Abstract]   [Full Text] [Related]  

  • 56. Oral alendronate in osteogenesis imperfecta.
    Unal E; Abaci A; Bober E; Buyukgebiz A
    Indian Pediatr; 2005 Nov; 42(11):1158-60. PubMed ID: 16340059
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intravenous pamidronate treatment in osteogenesis imperfecta.
    Fujiwara I; Ogawa E; Igarashi Y; Ohba M; Asanuma A
    Eur J Pediatr; 1998 Mar; 157(3):261-2. PubMed ID: 9537501
    [No Abstract]   [Full Text] [Related]  

  • 58. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.
    Rauch F; Travers R; Plotkin H; Glorieux FH
    J Clin Invest; 2002 Nov; 110(9):1293-9. PubMed ID: 12417568
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Genetic basis for skeletal disease. Osteogenesis imperfecta].
    Tanaka H
    Clin Calcium; 2010 Aug; 20(8):1245-52. PubMed ID: 20675936
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation and comparison of safety, convenience and cost of administering intravenous pamidronate infusions to children in the home and ambulatory care settings.
    Rush ET; DeHaai K; Kreikemeier RM; Lutz RE
    J Pediatr Endocrinol Metab; 2012; 25(5-6):493-7. PubMed ID: 22876544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.